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This study was carried out to systematically evaluate the degradation kinetics of 
gemcitabine hydrochloride injection solution over the pH region 1–12 at 70°C.  The 
degradation kinetics of gemcitabine were determined based on several parameters such as pH, 
buffer composition, temperature, ionic strength, and drug concentration.  A pH-rate profile was 
constructed using pseudo first-order kinetic rates at 70°C after buffer effect corrections; the 
observed pH-rate profile was characteristically U-shaped.  The degradation reactions of 
gemcitabine were found to be largely dependent on pH and were catalyzed by protons or 
hydroxyl groups at extreme pH values.  Gemcitabine shows maximum stability in the pH 
region 7–9.5.; however, due to its solubility limitations at pH ≥ 6, the gemcitabine injection 
solution stability at this pH range was not determined.  The gemcitabine injection solution at 
pH 2.5 showed a maximum stability of more than two years under the refrigerated conditions; 
this was derived from an Arrhenius plot.   The degradation of gemcitabine in 1 N HCl at 70°C 
for 4 weeks did not show any anomerization.  In contrast, α (0.01%) and -uridine (~ 40%) as 
analogues of gemcitabine were formed upon 4 weeks incubation under thermal conditions at 
70°C.  In this case, the water molecules acted as both acid and base to form α- and -uridines. 
A high level of anomerization to generate the α-anomer of gemcitabine and α-uridine was 
found in 0.1 N NaOH at 70°C for four weeks, while the -uridine (~ 20%) was observed at 
lower levels in this condition. Under basic conditions, a significant degradation product was 
formed; using NMR spectroscopy and mass spectrometry, it was determined  to be 1-(2-
deoxy-2,2-difluoro-α-D-erythro-ribopyranosyl)pyrimidin-2,4(1H,3H)-dione.    
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Gemcitabine hydrochloride is a -nucleoside (-isomer) chemically known as 2′-deoxy-2′, 2′-
difluorocytidine monohydrochloride (Scheme 1).  It is an antitumor agent that inhibits DNA 
synthesis [1].  Gemcitabine inhibits cellular proliferation in the synthesis phase (S-phase), and has 
shown activity against human leukemic cell lines and a number of solid tumor types in mice [2]. 
As a potential anticancer agent, it was originally evaluated for chemotherapy by Hertel et al. [3], 
and it is used in various carcinomas to treat non-small cell lung cancer, pancreatic cancer, bladder 
cancer, and breast cancer.  Gemcitabine is being investigated for use in oesophageal cancer, 
lymphomas, and various other tumor types.  There are indications that it has efficacy against 
pancreatic cancer in patients who have had successful tumor resections [4–8].  
  
Scheme 1: Structure of gemcitabine hydrochloride .  Its IUPAC name is 4-amino-1-[3,3-difluoro-
4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl]-1H-pyrimidin-2-one hydrochloride. 
(M.W: 299.66 amu, pKa = 3.6) 
 
 
The degradation of nucleosides, which undergo deamination under both acidic and basic 
conditions to produce the corresponding uridines, has been previously described [9].  In addition, 
several mechanisms for the acid-catalyzed cleavage of the N-glycosidic bond have been proposed, 
and anomerization of the nucleoside occurs under acidic conditions [10, 11].  Armstrong and 
coworkers reported the base-catalyzed anomerization of -5-formyluridine, which involves 




The analysis of gemcitabine by high-performance liquid chromatography (HPLC) [13–18] 
and microcalorimetry [19] has been previously described.  Anliker et al. [20] and Jansen et al. [21] 
studied the degradation of gemcitabine in solid and lyophilized forms in aqueous solution at the 
maximum temperatures of 40°C and 30°C, respectively.  However, there has been no kinetics and 
mechanism degradation study of the injection solution of gemcitabine nor any identification of its 
degradation products.  
In the present study, the degradation study of gemcitabine injection solution with 
identification of its degradation products was carried out to elucidate its possible degradation 
mechanisms.  The study was carried out at pH 1–12 under the influence of various buffer 
compositions, ionic strengths, temperatures, and drug concentrations.  The disappearance of the 
drug and the appearance of the degradation products were monitored by HPLC following a 
standard USP method [22].  Long-term solution stability was also determined at pH 2.5, and the 
study was designed to generate data to construct an Arrhenius plot.  This plot was used to 
extrapolate degradation rates at temperatures lower than those used in the study.  These rates can 
be used to estimate the shelf-life of solutions of gemcitabine at these lower temperatures.  The 
degradation of gemcitabine in injection solution was characterized and compared in acidic and 
basic solutions between 40°C and 70°C.  The degradation product found in basic solution at 70°C 
was not detectable at 40°C; this degradation product was isolated by semi-preparative HPLC and 






B. MATERIALS AND METHODS 
B.1.  Materials: 
Gemcitabine hydrochloride standard was purchased from USP for formulation preparation and 
method analysis.  Cytosine standard also was purchased from USP.  All other standard compounds 
such as α-anomer of gemcitabine, α-uridine and -uridine were purchased from Toronto Research 
Chemicals (TRC), Toronto, Ontario, Canada.  HPLC-grade methanol was obtained from Burdick 
& Jackson, Muskegon, MI, USA.  Reagent-plus grade or ACS reagent grade monobasic sodium 
phosphate (anhydrous), ortho-phosphoric acid, hydrochloric acid, sodium hydroxide, and LC/MS 
grade ammonium formate and formic acid were purchased from Fisher, Waltham, MA, USA.  
Milli-Q water was obtained from a Millipore water purification system (Millipore, Billerica, MA, 
USA). 
B.2. Gemcitabine Hydrochloride Injection Solution Formulation Preparation: 
The water used in the study was purged with nitrogen gas. Thereafter, the gemcitabine 
hydrochloride, USP standard (amount adjusted for hydrochloride salt in gemcitabine 
hydrochloride) was mixed with this nitrogen-purged water and mixed well until the dissolution 
was completed.  The pH of the solution was maintained between 2 and 3, and the pH was adjusted 
using HCl or NaOH solution when needed.  After the pH adjustment, the final bulk solution was 
purged again with Nitrogen.  The final concentration of the drug molecule in the gemcitabine 
hydrochloride injection solution obtained was 38 mg/mL.  The gemcitabine injection solution was 






B.3. Buffer Solutions: 
For the kinetic studies, the following aqueous buffer solutions were used: hydrochloric acid 
for pH 1.7 and 2.0; phosphate (pKa1) for pH 2.7 and 3.1; acetate for pH 4.1 and 5.3; phosphate 
(pKa2) for pH 6.0, 7.0 and 8.0; carbonate (pKa2) for pH 9.3, 10.4 and 11.0; phosphate (pKa3) for 
pH 11.5; and sodium hydroxide for pH 10.9, 11.4 and 12.0.  The pH values were measured at the 
study temperature using an Orion Ross Ultra pH electrode (ID#8102BNUMP, Thermo Scientific, 
Chelmsford, MA, USA) and a pH meter (Orion 3 Star, Thermo Scientific, Chelmsford, MA, USA).  
For a constant ionic strength (µ) of 0.3 M, each solution was adjusted with an appropriate amount 
of sodium chloride.  This was not the case for solutions used in the experiments in which the ionic 
strength was varied.  No significant changes in pH were observed throughout the degradation 
studies.  
B.4. Kinetic Measurements of Drug Degradation: 
The influences of various external factors on the degradation process were studied. To 
construct the pH-rate profile, the pH was varied between 1 and 12 at 70°C. Values for kobs were 
calculated at constant pH, ionic strength, and temperature.  Different buffer concentrations were 
used to determine the effect of buffer ions on the rates of degradation.  The influence of ionic 
strength on the chemical stability of gemcitabine was investigated with 0.01 M buffer solutions at 
pH 2.5, 7.0, and 11.0 at 70.0 ± 0.2°C.  The ionic strength was varied between 0.05 and 1.0 M by 
adding various amounts of sodium chloride.  Degradation of gemcitabine was investigated at 42.0, 
60.0, 70.0 and 80.0° ± 0.2°C in 0.01 M carbonate buffer at pH 11.0; in 0.01 M phosphate buffer at 
pH 7.0; and in 0.01 M hydrochloric acid at pH 2.5.  The concentration of gemcitabine was varied 
between 198 and 1520 µg/mL in 0.01 M buffer solutions at pH 2.5, 7.0, and 11.0 with temperature 




sample of gemcitabine injection solution with an initial concentration of 38 mg/mL to 10 mL of 
the buffered solution to obtain an initial gemcitabine concentration of 198 µg/mL (7.5 × 10–4 M).  
Before adding gemcitabine, the buffer solutions were preheated to the temperature of the study.  
The stock solution of gemcitabine in water was kept at 4°C, and the drug was stable at this 
temperature for at least 4 weeks.  Reaction solutions were kept in crimped capped glass vials in a 
thermostatically controlled water bath in the dark. All kinetics experiments were performed in 
duplicate [23–25]. 
At appropriate time intervals, 500 µL samples were withdrawn from the above reaction 
solutions and added to 500 µL of a precooled (4°C) 0.1 M phosphate buffer solution, pH 7.  When 
the degradation of gemcitabine in buffer solutions of various molarities was studied, 500 µL of a 
0.5 M phosphate stock solution was used to bring the reaction mixtures to 0.1 and 0.2 M buffer 
concentrations at a neutral pH.  The final concentrations of the samples were at ~ 0.1 mg/mL.  
Until they were analyzed (within 2–5 days), the samples were kept at 4°C which stabilized the 
samples for this period of time.  All samples belonging to the same experiment were analyzed on 
the same day by a stability indicating HPLC assay and impurity methods.  UV spectra were 
measured for solutions that were processed in the same way as those used for HPLC analysis. 
B.5. Degradation Chemistry: 
      Heat-degraded impurity sample solution (2 mg/mL) was prepared by transferring 1.32 mL of 
gemcitabine injection solution sample (38 mg/mL) into a 25 mL volumetric flask, and then placing  
it in an oven at 70°C for 4 weeks.  After 4 weeks, the degraded sample solution was diluted to 
volume with milli-Q-water.  The impurity sample solution was then diluted to a gemcitabine 




Acid-degraded impurity sample solution (2 mg/mL) was prepared by transferring 1.32 mL of 
gemcitabine injection solution sample (38 mg/mL) in 0.5 mL of 1.0 N hydrochloric acid into a 25 
mL volumetric flask, and then placing the sample in an oven at 70°C for 4 weeks.  After 4 weeks, 
the degraded sample solution was neutralized with 1 N sodium hydroxide and diluted to volume 
(25 mL) with milli-Q-water.  The impurity sample solution was diluted to a gemcitabine 
concentration of 0.1 mg/mL for assay. 
Sample solution for degradation in basic conditions (2 mg/mL) was prepared by transferring  
1.32 mL of gemcitabine injection solution sample (38 mg/mL) in 0.5 mL of 0.1 N sodium 
hydroxide into a 25 mL volumetric flask, and placing it in an oven at 70°C for 4 weeks.  After 4 
weeks, the degraded sample solution was neutralized with 0.1 N hydrochloric acid and diluted to 
volume (25 mL) with milli-Q-water.  The impurity sample solution was then diluted to a 
gemcitabine concentration of 0.1 mg/mL for assay.  1.5 mL aliquots of all the above assay and 
impurity sample solutions were transferred into HPLC vials for sample injections.  
B.6. Analytical HPLC: 
Chromatographic separation of gemcitabine and its degradation products was performed on an 
Agilent HPLC system equipped with 1200 series pump, photo diode array detector, and auto 
sampler. For analytical HPLC, a Zorbax RX-C8 column (250 × 4.6 mm, 5 μ particle size), Agilent, 
Santa Clara, CA USA) was used for the separation of all known and unknown impurities from 
gemcitabine. The USP method that was used to separate the degradation products of gemcitabine 
involved  mobile phase A and mobile phase B.  Mobile phase A was a buffered solution that 
consisted of 13.8 g of anhydrous sodium phosphate monobasic and 2.5 mL of phosphoric acid in 
1 L milli-Q water at pH 2.4–2.6. Mobile phase B consisted of methanol. The initial composition 




increased to 50% over a 5-min period and was maintained at this level for 7 min prior to returning 
to the initial mobile phase composition over a 15-min period.  Before initiating sample injections, 
the column was allowed to equilibrate for approximately 30 min. For both assay and impurity 
methods, the chromatography was performed at ambient conditions, the flow rate was 1.2 mL/min, 
and the sample injection volume was 20 µL.  The chromatograms were obtained at 275 nm.  
Sample concentration was ~0.1 mg mL–1 prepared in buffer for kinetic measurements study. 
B.7. Semi-Preparative HPLC Sample Preparation: 
To isolate and identify the degradation product, 2.0 mL of 6 N sodium hydroxide solution was 
added to 12 mL of gemcitabine hydrochloride injection solution (concentration 38 mg/mL) in a 25 
mL volumetric flask; then the mixture was placed in an 80°C oven for 5 h.  After 5-h incubation, 
sufficient 1 N hydrochloric acid was added to neutralize the solution followed by dilution with 
milli-Q water to 18 mg/mL concentration of gemcitabine hydrochloride.  The isolated degradation 
products from semi-preparative HPLC were collected using a fraction collector.  The fractions 
from preparative chromatography containing the desired product were combined and concentrated 
at room temperature under high vacuum on a Buchi Rotavapor R-134 by rotary evaporation.  The 
isolated unknown sample was analyzed for impurities using analytical HPLC; the structure of the 
isolated sample was then characterized using LC/MS-MS and NMR.  
For semi-preparative HPLC, a X-Select C18 (150 × 10 mm, 5 μ particle size, Waters, Milford, 
MA USA) preparative column was used for the sample injections.  The data were collected and 
processed using Agilent “Chemstation” 1200 series software.  A linear gradient program was 
optimized for the separation of unknown degradation product from gemcitabine and other known 
degradation products where it consisted of mobile phase A and moblile phase B.  The mobile phase 




phase B consisted of methanol.  The initial composition of mobile phase A and B was of  97:3 
(v/v) for 8 min.  The amount of mobile phase B was then increased to 50% over a 3-minute period 
and was maintained at this level for 5 min prior to returning to the initial mobile phase composition 
over a 10 minute period.  The flow rate was set at 5 mL min–1.  The UV detection wavelength was 
at 275 nm.  For each sample injection, 300 μL of the above sample concentration, 18 mg/mL (refer 
to Semi-Preparative HPLC Sample Preparation) was injected into the prep-HPLC system. 
B.8. Mass Spectroscopy (LC-MS/MS): 
The collected fraction at 0.5 mg/mL in milli-Q water was subjected to LC-MS/MS analysis to 
identify the degradation product.  LC-MS/MS analysis was performed on LTQ Velos (Thermo 
Fisher Scientific, Waltham, MA, USA) coupled with an HPLC system consisting of an Agilent 
1200 series low pressure quaternary degasser, auto sampler, and column oven.  A Zorbax RX-C8 
(250 × 4.6 mm, 5 μ particle size) HPLC column was used for the separation of all known and 
unknown impurities from gemcitabine.  The analysis was done in a positive electrospray ionization 
(ESI) mode with turbo ion spray interface under the following conditions: ion source voltage IS = 
3800 V; declustering potential, DP = 70 V; focusing potential, FP = 400 V; capillary temperature 
= 400°C; entrance potential, EP = 10 V with nitrogen gas as nebulizer at 40 psi and curtain gas as 
nitrogen at 25 psi.  
The USP impurities method was optimized for the separation of the impurities from 
gemcitabine where the initial mobile phase consisted of mobile phase A (10 mM ammonium 
formate buffer solution, pH 2.75) and mobile phase B (methanol) in a ratio of 97:3 (v/v) for 8 min.  
The percentage of mobile phase B was then increased to 50% over a 5-min period.  This ratio 
(mobile phase A and B in the ratio 50:50 (v/v)) was held for 7 min and brought back to the initial 




equilibrate for approximately 30 min.  The chromatography was performed at ambient condition, 
and the flow rate was 0.9 mL/min.  The chromatograms were obtained at 275 nm. Sample 
concentration was ~0.1 mg mL–1 prepared in milli-Q water.  Mass fragmentation studies were 
carried out by maintaining normalized collision energy at 35 V with a range of m/z 70–500 amu. 
B.9. NMR Spectroscopy: 
The 1H and 13C NMR studies of the isolated degradation products were carried out in methanol-
d4 at 25°C using 400 and 500 MHz Bruker Avance NMR spectrometers, respectively.  The 1H  
and 13C chemical shifts (δ) are reported in ppm. 
C. RESULTS AND DISCUSSION 
The degradation kinetics of gemcitabine gemcitabine injection solution were investigated over 
the pH range 1–12 at 70°C.  High-performance liquid chromatography (HPLC) using standard 
USP methods for determining assay and impurities were used for these studies.  To determine the 
degradation kinetics of gemcitabine injection solution, the effects of pH, ionic strength, buffer 
concentrations, temperatures, and drug concentrations on the degradation kinetics were 
evaluated.  Arrhenius plots were constructed to determine the effect of activation energy on the 
reaction mechanism at different pH levels. In addition, this plot was used to determine the long-
term solution stability (t95%) of gemcitabine injection solution at pH 2.5.  The known degradation 
products in thermal, acidic, and basic conditions were identified by respresentative impurity 
standards, and one unknown degradation product under basic conditions was isolated and 
identified using NMR and mass spectrometry. 
C.1. Time-Dependent Degradation of Gemcitabine: 
Time-dependent disappearance of GM (198 µg/mL, 7.5 × 10–4 M) and the appearance of the 




degradation products reached 60% relative to the initial amount of gemcitabine (Figure 1 and Table 
1).  The amount of degradation product reached 60% of the starting gemcitabine concentration 
after 3-h stress conditions, and the amount reached a plateau at 60% after 3 h (Figure 1 and Table 
1).  The mass balance that accounted for observed degradation products did not reach a total of 
100% (Figure 1).  This result suggests that there were additional degradation products that could 
not be detected using the USP standard method for impurity at a wavelength of λ = 275 nm.  The 
disappearance of gemcitabine in this sodium hydroxide medium follows pseudo first-order kinetics 
(Figure 1), which is determined by linearity of the plot of the natural logarithm of residual 
concentrations of gemcitabine vs. time at pH 12 (Figure 1).           
Table 1: Time-dependent disappearance of GM and the appearance of the degradation 














0 101 4.6 0.99 102.0 
1 59 4.1 37.6 96.6 
2 34 3.5 53.5 87.5 
3 19 2.9 60.8 79.8 
4 12 2.5 61.1 73.1 
5 7 1.9 62.4 69.4 





C.2. pH-Rate Profile of Gemcitabine at 70°C: 
The pH-rate profile was constructed using the degradation rates at 70°C, µ = 0.3 M, and various 
pH values corrected for buffer effects (Figure 2).  All rate constants obtained from individual plots 
of natural logarithms of sample concentration vs. time are shown in Table 2; and the specific rate 
constants were calculated using a non-linear least-squares curve fitting program (Table 4).  The 
pH-rate profile shows three different regions corresponding to proton catalyzed (pH 1–6), water 
catalyzed (pH 7–9.5) and hydroxyl ion catalyzed (pH 10 – 12) degradation reactions, according to 
the following formula: 
 
Figure 1: Time-dependent disappearance of gemcitabine and the appearance of the 
degradation product measured in a NaOH solution (conc. = 1 M) at pH 12 and 70°C with 
sample concentration = 198 µg/mL or 7.5 × 10-4 M. The Y-axis on the left represents the 
amount of degradation product formed relative to the initial amount of gemcitabine.  The Y-
axis on the right represents the amount of gemcitabine remaining. ( represents the mass 
balance of gemcitabine.  ∆ represents the amount of gemcitabine remaining at that time.   
represents natural logarithm of percent amount gemcitabine, which follows pseudo first-order 




























































































kobs = k0 + kH+[H+] + kOH–[OH-] + kbuff [Buffer]            (Eq. 1) 
In this case,  k0 is the rate constant of the water catalyzed reaction; kH+ is the rate constant of the 
proton-catalyzed reaction; kOH–  is the rate constant of the hydroxyl ion-catalyzed reaction. and 
kbuff  is the rate constant of the protonated and deprotonated buffer molecule-catalyzed reactions. 
The degradation reactions of gemcitabine were observed as largely dependent on pH, where proton 
or hydroxyl catalysis occurs at extreme pH regions.  Maximum stability was observed in the pH 
region 7.0–9.5; however, due to solubility limitations at pH ≥ 6 [26], this region was not considered 
for long-term stability determination.  The kH+ has been calculated from the straight line in the pH 
region 1–6 at 70°C (Table 4).  The slope of –0.5 shows that something more than specific proton 
catalysis is likely going on (Figure 2).  At the region of pH 7–9.5, K0 was calculated where in this 
region log kobs equals k0 (Figure 2 and Table 4).  The kOH– has been calculated from the straight 
line in the pH region 10–12 at 70°C (Figure 2 and Table 4).  The observed slope of +1.5 indicates 









Figure 2: pH-rate profile of gemcitabine injection solution at 70°C obtained by 
extrapolation to zero buffer concentration.  kH+ = the intercept on the y-axis from the 
portion of the pH-rate profile between pH 1–6. (Slope = –0.5 shows something more than 
specific proton catalysis).  From the region pH 7 – 9.5, log kobs = k0 (no solvent effect) .  
kOH- = the straight line in the pH region 10 – 12 at 70°C. (Slope = +1.5 shows something 




















Table 2: Summary of rate constants for degradation of gemcitabine injection solution in 




Rate Constant  
kobs  (s–1) × 10–5 log kobs pH 
Sodium 
Hydroxide 0.10 0.8 –5.10 10.9 
Sodium 
Hydroxide 0.25 3 –4.52 11.4 
Sodium 
Hydroxide 1 10 –4.00 12.0 
Hydrochloric 
Acid 0.005 0.2 –5.70 2.0 
Hydrochloric 
Acid 0.01 0.3 –5.52 1.7 
Phosphate (pKa1) 0.01 0.1 –6.00 2.7 
Phosphate (pKa1) 0.01 0.07 –6.15 3.1 
Acetate 0.01 0.02 –6.70 4.1 
Acetate 0.01 0.005 –7.30 5.3 
Phosphate (pKa2) 0.01 0.002 –7.70 6.0 
Phosphate (pKa2) 0.01 0.001 –8.00 7.0 
Phosphate (pKa2) 0.01 0.0009 –8.05 8.0 
Carbonate (pKa2) 0.01 0.001 –8.00 9.3 
Carbonate (pKa2) 0.01 0.08 –6.10 10.4 
Carbonate (pKa2) 0.01 1* –5.00 11.0 
Phosphate (pKa3) 0.01 4* –4.40 11.5 
*Influence of buffer study was conducted with various buffer concentrations (0.05 – 0.2 




C.3. Influence of Carbonate or Phosphate Concentrations on kobs for the Degradation at 70°C: 
Among all buffers, carbonate and phosphate buffers were studied initially to observe 
significant effects on rate constant (kobs) at pH region 11–11.5 (Table 3).  Apparently, a proton 
transfer can take place as a part of the degradation mechanism in this pH region.  Parallel level 
curves observed for both carbonate and phosphate in different buffer concentrations (0.005 M to 
2.0 M) (Table 3 and Figure 3).  To delete the influence of buffer ions on kobs, all kobs values in the 
pH region 11–11.5 have been extrapolated to zero buffer concentration, resulting in the corrected 
kobs in the pH rate profile, where the corrected kobs for carbonate buffer at pH 11.0 is 1 (y intercept 
= 0.7995) and for phosphate buffer at pH 11.5 is 4 (y intercept = 3.623) (Figure 3).  Since the 
carbonate and phosphate buffers were observed with parallel level curves, for all other buffers 
below pH 11, the kobs should have even less or no effect in various buffer concentrations between 
0.05 and 0.2 M.  Therefore, for all other buffers below pH 11, the buffer concentration used was 
0.01 M and the final ionic strength was adjusted to 0.3 M with sodium chloride.  
 
Table 3: Influence of carbonate and phosphate concentration on kobs of the 
degradation reaction of gemcitabine. 
Buffer 
Concentration (M) 
Carbonate (pKa2) pH 11.0,  
kobs  (s–1) × 10–5 
Phosphate (pKa3) pH 11.5, 
kobs  (s–1) × 10–5 
0.005 1.0 4.0 
0.01 0.6 3.0 
0.05 1.0 4.0 
0.1 0.6 4.0 





After the correction for buffer catalysis was made for the carbonate and phosphate buffers, the 
kH+ and kOH– were calculated as the intercepts on the y-axis from the portion of the pH-rate profile 
between pH 1–6 and 10–12, respectively (Figure 2).  The specific rate constants were calculated 
with the use of a non-linear least-squares curve fitting program (Table 4).  
 
Table 4:  Specific rate constants of the degradation of gemcitabine at 70°C
kH+ 2.22 × 10–5 s–1 
k0 8.90 × 10–9 s–1 
kOH– 1.79 × 10–3 s–1 
 
 
Figure 3: Influence of carbonate concentration at pH 11.0 and phosphate concentration at 
pH 11.5 on kobs for the degradation of gemcitabine at 70°C. Parallel curves were observed 
for both carbonate and phosphate buffers at different concentrations (0.005 M to 2.0 M).  The 
kobs values at pH 11 and 11.5 have been extrapolated to zero buffer concentration to delete 
the influence of buffer ions, resulting in the corrected kobs in the pH-rate profile.  The 
corrected kobs for carbonate buffer has a y intercept at 0.7995 and for phosphate buffer has a 



























Influence of Carbonate and Phosphate buffer concentration on 




C.4. The Effect of Ionic Strength on the Degradation of Gemcitabine: 
The influence of ionic strength on the chemical stability of gemcitabine was investigated at 
drug concentration of 198 µg/mL with 0.01 M buffer solutions at pH 2.5, 7.0, and 11.0 and 70.0 ± 
2°C.  The ionic strength was varied between 0.05 and 1.0 M upon addition of various amounts of 
sodium chloride (Table 5).  At both pH 2.5 and 7.0, there was no increase in the rate of degradation 
upon the increase in ionic strengths.  In contrast, the reaction rate increased at pH 11 when the 
ionic strength was increased from 0.1 M to 1.0 M in carbonate buffer solution (0.01 M), indicating 
that there is an influence of ionic strength (Figure 4).  No influence of ionic strength (µ = 0.05 – 
1.0 M) on the chemical stability of gemcitabine injection solution was observed in 0.01 M 
phosphate buffers at pH 2.5 (pKa1) and pH 7 (pKa2).  The carbonate buffer (pKa2) with pH 11 was 
observed to have an increased rate constant as the ionic strength of the buffer solution increased at 
> µ= 0.1.  This result indicates that a reaction between at least two charged particles does not play 
an important role in the degradation mechanism of gemcitabine. 
 







kobs  (s-1) x 10-5 
pH 7 
Phosphate Buffer (pKa2) 
kobs  (s-1) x 10-5 
pH 11 
Carbonate Buffer 
(pKa2) kobs  (s-1) x 
10-5 
0.05 0.1 0.0006 0.5 
0.10 0.1 0.002 0.4 
0.30 0.1 0.002 0.5 
0.60 0.1 0.001 0.7 





Ugye et al. observed a linear dependence behavior on the effect of ionic strength on the rate 
constant of the reaction between formaldehyde and plasma albumin in water solution at neutral pH 
7.0 and 37°C [27].  Pablo Valenzuela et al. had studied the effects of ionic strength of carbonate 
buffer at pH 11.1 on the kinetics of the acetylated--chymotrypsin that catalyzes the hydrolysis of 
N-acetyl-L-tryptophan methyl ester.  They observed a linear increase in the rate constants during 
the increase in ionic strength from µ = 0.1 to 0.5; however, further increase of the ionic strength 
to µ = 1.0  decreases the rate constant (Table 4) [28].  As a result, it can be predicted for 
gemcitabine in carbonate buffer at pH 11 (pKa3) that the increase in ionic strength produced will 
increase the rate of degradation.  
Figure 4: Buffer degradation at different pH vs Ionic Strength Plot: For pH 2.5 & 7.0 buffers, 
no influence on the rate of degradation observed upon increasing the ionic strength.  For pH 
11 buffer, rate of reaction linearly increased as the ionic strength (µ = 0.1 – 1.0 M) increased. 
( represents pH 2.5, phosphate buffer, pKa1.   represents pH 7, phosphate buffer, pKa2.  



























C.5. The Role of Drug Concentration on Degradation: 
The effect of sample concentrations on gemcitabine degradation was evaluated at various pH 
values at 70°C  (Table 6 and Figure 5).  Sample concentrations were varied from 198 to 1520 µg 
mL-1, and degradation studies were conducted at pH 2.5, 7.0, and 11.0.  The results showed no 
change in kobs at different drug concentration at pH 2.5 and 7.0 with phosphate buffer.  In carbonate 
buffer at pH 11.0, there was no change in rate constants from 198 to 1140 µg mL–1; however, there 
was a decrease in kobs at a concentration of 1520 µg mL–1.  In summary, only at a high drug 
concentration (1520 µg mL–1) at pH 11.0, the rate of drug degradation is slower, it may be due to 
a possible sample precipitation.  
 
 
Table 6: Rate constant of different buffers in different sample concentrations 
Sample Concentration (µg 
mL–1) 
(pH 2.5) Rate 
Constant 
 kobs  (s–1) × 10–5 
(pH 7) Rate 
Constant  
kobs  (s1) × 10–7 
(pH 11) Rate 
Constant 
kobs  (s–1) × 10–5 
198 0.1 0.2 0.5 
380 0.1 0.02 0.5 
760 0.1 0.09 0.5 
1140 0.1 0.03 0.5 






C.6. Temperature Effects on the Degradation Reaction: 
The impact of temperature on drug degradation at  pH 2.5, 7.0, and 11.0 was studied.  The 
Arrhenius equation was used to describe the effects of temperature on three different parts of the 
pH-rate profile; 
ln kobs (T) = ln A – EA/R × 1/T                (Eq. 2) 
where A is the frequency factor, EA is the activation energy, R is the gas constant (8.314 J mol–1 
K–1), and T is the temperature (K).  The degradation rate constants of gemcitabine were derived 
Figure 5: Plot of rate constant vs. sample concentration with different buffers at 70°C.  For 
pH 2.5 and 7.0 buffers, no influence on the rate of degradation was observed upon increasing 
the sample concentrations.  For pH 11 buffer, there was no change in rate constant except at 
sample concentration 1520 µg mL–1, which falls from level plot. ( represents pH 2.5, 
phosphate buffer, pKa1.   represents pH 7, phosphate buffer, pKa2.  ∆ represents pH 11, 




























from the concentration data obtained on the thermally stressed solutions at four different 
temperatures at pH 2.5 and three temperatures at pH 7 and pH 11.  Table 7 shows the time vs. 
natural log of concentrations of gemcitabine at pH 2.5 and various temperatures, and these data 
were used to generate the pseudo first-order degradation plots (Figure 6). 
 
Table 7:  Time vs. assay results of gemcitabine Injection Solution of pH 2.5 (phosphate 
buffer, pKa1) at 42°C, 60°C, 70°C, and 80°C 
Time (day) ln A (A = % 
w/w Assay 
Result) at 42°C 
ln A (A = % w/w 
Assay Result) at 
60°C 
ln A (A = % 
w/w Assay 
Result) at 70°C 
ln A (A = % 
w/w Assay 
Result) at 80°C 
0 4.6 (99.7 %) 4.6 (103.3 %) 4.6 (95 %) 4.6 (95.5 %) 
2 --- --- --- 4.2 (64.2 %) 
4 --- 4.4 (83.9 %) 4.3 (74.5 %) --- 
5 --- --- --- 3.5 (33.7 %) 
6 4.6 (96.5 %) --- ---  
7 --- --- --- 3.1 (22 %) 
9 --- 4.3 (70.2 %) 3.9 (48 %) 2.6 (14 %) 
10 4.6 (95.6 %) --- --- --- 
12 --- --- 3.6 (36.5 %) 2.0 (7.3 %) 
15 --- 4.1 (59.1 %) --- --- 
16 4.5 (93 %)  3.2 (24.6 %) --- 
19 --- 3.9 (51.7 %) --- --- 
20 --- --- 2.8 (16.5 %) --- 
21 4.5 (89.5 %) --- --- --- 
22 --- 3.9 (47.5 %) --- --- 
34 4.4 (82.3 %) --- --- --- 
Rate 
Constant, k  
(day–1) 
0.0056 0.0342 0.0887 0.2151 














The influence of different temperatures on the degradation of gemcitabine at pH 2.5, 7.0, and 
11.0 was studied.  Arrhenius plots were constructed to determine their respective activation 
energies. The linearity of the plot of (kT) vs. 1/T indicates that the degradation of gemcitabine does 
follow the Arrhenius equation (Figures 6 and 7).  The calculated parameters were extracted from 
the Arrhenius plot and are shown in Table 8.  The activation energy at pH 2.5, 7.0, and 11.0 
assumed to show different reaction mechanisms of the proton, solvent, and hydroxyl ion-catalyzed 
degradation reaction, respectively  (Table 8).  
 
Figure 6: Pseudo first-order plots of the degradation of gemcitabine at the four different 
temperatures in phosphate buffer (pH 2.5) at various temperatures.  (, 42°C; , 60°C, ∆, 





































 Table 8: Parameters from the Arrhenius equation 
pH  A (day–1) EA (J mol–1)  R2 
2.5 2.94 × 1012 8.88 × 104 1.0000 
7 7.32 × 1017 1.37 × 105 1.0000 





Figure 7. Arrhenius plot for the degradation of gemcitabine at pH (A) 2.5 and (B) 7.0 and 









































The activation energy at pH 2.5 is lower than those at pH 7 and 11 (Table 8) and this difference 
is possibly due to the difference in degradation mechanism at pH 2.5 compared to that at pH 7 and 
11.  The degradation at pH 2.5 may involve proton catalysis, while at pH 7 and 11 the degradation 
mechanisms may involve solvent and/or hydroxyl ion, respectively.  At 80°C and pH 7, only 5% 
gemcitabine was converted into the degradation product while 80% of gemcitabine was converted 
to the degradation product at pH 11.  It is expected that gemcitabine is more stable in mild 
conditions (pH 7) than the relatively harsh conditions at pH 11. It is interesting to find that the 
degradation products of gemcitabine at both pH 7.0 and 11 are the same.  Although the activation 
energies at pH 7 and 11 are similar (Table 8), the amount of degradant at pH 7 is lower than at 11; 
this is presumably due to the difference in degradation mechanisms and the rates of degradation. 
C.7. Shelf Life (t95%) of GM Injection Solution at pH 2.5 at 5°C and 25°C: 
The Arrhenius plot can be used to calculate degradation rate constants at 25°C and 5°C for  pH 
2.5 (Figure 7) followed by calculation of the shelf life of gemcitabine (t95%) at these temperatures 
(Table 9).  The calculated shelf-lives for gemcitabine (t95% ) are 64 days incubated at 25°C and  
2.3 years at 5°C.  This result suggests that the injection solution of gemcitabine would be feasible 
for use in the clinic from the standpoint of chemical stability if it is stored under refrigeration. 
 
                           Table 9: Gemcitabine Injection Solution t95% at 5°C and 25°C 
A (day–1) EA /R (J mol–1) t95% at 5°C (year) t95% at 25°C (days) 






C.8. Mechanism of Degradation of Gemcitabine: 
The degradation of lyophilized form of gemcitabine hydrochloride was previously studied by 
Anlinker et al. [20] and Jansen  et al. [21]; however, the stability study of gemcitabine injection 
solution had not been carried out.  Thus, this study was done to evaluate the difference in the 
degradation pathway of an injection solution compared to that of a lyophilized formulation.  The 
degradation study of gemcitabine injection solution was carried out under thermal, acidic, and 
basic conditions at 70°C for one month, and the degradation products were isolated by HPLC and 
characterized by NMR and mass spectrometry (MS).  In a thermal study at 70°C, the gemcitabine 
injection solution was degraded up to 94%, and the main degradant product was beta uridine 
(Scheme 1), which was proposed by Jansen et al. [21]. In this current study, a minor product 
(0.01%) of -uridine was also observed (Scheme 2). It is noteworthy that 0.4% β-uridine was 
already formed in gemcitabine injection solution under refrigerated conditions (Figure 8A); 
however, the heated sample contained 39.58% of -uridine (Figure 8B). 
 
Scheme 1: Proposed deamination pathway of gemcitabine to form -uridine. 




All of the different stress conditions (i.e., heat, acid, and base) produced -uridine; however, a 
lower amount of -uridine (20.21%) was observed in basic conditions compared to thermal and 
acidic conditions. In contrast, a  higher level of α-uridine was found in basic conditions compared 
to the acidic conditions (Scheme 2).   
 
A new degradation product, 1-(2-deoxy-2,2-difluoro-α-D-erythro-ribo-pyranosyl)pyrimidine-
2,4(1H,3H)-dione, was found under basic conditions at 70°C.  This product was isolated using 
semi-preparative HPLC and characterizd by 1H and 13C NMR and LC/MS/MS. Gemcitabine 
solution (10 mg/mL) was incubated in acidic solution (1 N HCl) for 4 weeks at 70°C, 
and 1.5% of gemcitabine remained after 4 weeks as determined by HPLC.  The 
 





amount of -uridine degradation product in the acid conditions was 40.51% compared 
to 39.58% for the heat-stressed sample of gemcitabine injection solution.  This result 
suggests that the formation of -uridine was not due to the presence of acid but to 
heat degradation (Figure 8).  The -uridine was also observed under this thermal acid 







Figure 8: HPLC profiles of 2 mg/mL gemcitabine injection solution after 4 weeks of (A) 
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stressed samples at 70°C produced a similar amount of -uridine (about 0.01%), 
suggesting that the acid did not influence any further formation of -uridine.  The 
cytosine base, which elutes at around 2.6 min in the HPLC assay (Figure 8), was not 
observed as a degradation product under either heat or acidic conditions.  Therefore, 
the cleavage of the cytosine base from the sugar does not occur under heat and acidic 
conditions at the elevated temperature of 70°C.  This finding is consistent with the 
work of Nugye and Notari [29], which indicated that un-substituted cytosine 
nucleosides degrade primarily by heat-independent deamination rather than by 
cleavage of cytosine from the sugar.  
Gemcitabine injection solution (10 mg/mL) was degraded in a basic solution (0.1 
N NaOH) for 4 weeks at 70°C (Figure 9). After 4 weeks, 21% of gemcitabine 
remained in solution.  Three degradation products were observed, including -
anomer, -uridine and -uridine as were previously isolated and identified by Sally 
et al. [20].  The -uridine was the heat degradant and was observed in all three stressed 
conditions, heat, acidic, and basic conditions at 70°C.  The -uridine formation was 
 
Figure 9:  HPLC profiles of 2 mg/mL gemcitabine injection solution after 4 weeks of 
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due to protonation and deamination by water molecules at 70°C.  The -anomer was 
formed due to neucleophilic hydroxide attack on the gemcitabine; this formation was 
unique; forming only under basic-stressed conditions at both 40°C and 70°C (Scheme 
3).  The formation of an alpha anomer as shown in Scheme 3 had been proposed by 
Sally et al. [20].  The formation of -uridine was due to protonation and deprotonation 
of gemcitabine by hydronium ion and hydroxide ion at 70°C. A higher level of -
uridine was observed in basic-stressed solution as compared to heat- and acid stressed 
sample solutions at 70°C.  Therefore, it is evident that -uridine formation is also 
sensitive to nucleophilic attack of hydroxide ions.  
 
 
Scheme 3: Proposed deamination pathway of gemcitabine and formation of α-anomer   




C.9. Characterization of Degradation Products:  
To generate and isolate the degradation products, gemcitabine was incubated in 6 
N NaOH at 80°C for 5 h.  There were three unknown degradation products that were 
eluted at 13.16 min, 15.01 min, and 15.75 min at retention times (RT) (Figure 9).  
Two of those three unknown impurities were not stable under higher thermal basic 
reaction conditions.  The isolated unknown product with RT of 15.01 was confirmed 
by HPLC-PDA analysis to be a pure component (area = 96%) by the purity angle 
(0.825), which is less than the purity threshold (1.021) (Figure 10).  This isolated 
impurity was used for further spectroscopic characterization using  LC-MS/MS, 1H 
NMR and 13C NMR.   
 
The degradation of gemcitabine was monitored using UV spectroscopy (Figure 11, 
Table 10).  The UV spectrum of the isolated unknown product with RT of 15.01 was 
observed at 256 nm (Figure 11A), suggesting that the unknown product has 
absorbance from a chromophore of cytosine base, which is similar to those from - 
and -uridine.  The spectra of mixed known degradation products and unknown 
Figure 10: Chromatogram of HPLC-PDA analysis for purity of an unknown degradation 
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(B)   
 
 
(C)   
 
 Figure 11: (A) The UV spectrum of an unknown degradation product with a λmax of 256 
nm.  (B) The UV spectra of mixed known impurities.  The peak at λmax of 276 nm is for α-
anomer (red). The peak at λmax of 259 is for α-uridine (blue).  The peak at λmax 258 is for -
uridine (green).  (C) The UV spectrum of an unknown degradation product of gemcitabine 
injection solution (2 mg/mL) after 4-weeks incubation in a basic condition at 70°C. The peak 




Table 10: UV and mass spectra of degradation of known and 
unknown impurities. 




α-anomer 4.97 276 
α-uridine 12.91 259 
-uridine 14.07 258 
Unknown Impurity in the 
base sample  






The isolated unknown compound was also evaluated using mass spectrometry; it has a 
molecular ion peak at m/z for [M+H]+ at 265.  The primary fragment of the parent peak was found 
at m/z 112 amu, which was from deaminated cytosine base due to the elimination of the ribose 
group (Figure 12).  The deaminated cytosine base (m/z = 112 amu) was also formed as the primary 
degradation peak and fragmentation pattern for α-uridine (Figure 13 A and B) and -uridine 
fragmentation pattern (Figure 13 C and D).  On the other hand, the primary peak and fragmentation 
pattern for α-anomer was cytosine base (m/z = 111 amu) (Figure 13 E and F).  Therefore, the 
unknown impurity contains the same m/z mass spectrum and has a fragmentation pattern similar 
to that of α- and -urdine.  Because the formation of -urdine is more favorable than that of -
uridine under basic condition, it is proposed that the unknown product contains a cytosine-
deaminated base at the α position.  Based on the m/z fragmentation pattern, a reaction pathway for 








Scheme 4: A proposed pathway for the formation of ribose ring formation in the 











Figure 12: The mass spectrometry spectrum of the isolated unknown degradation product 
















Figure 13: The respective LC-MS and MS/MS mass fragmentation spectra of 




The 1H and 13C chemical shifts from the NMR spectra of various compounds are 
listed in Table 11.  The 1H-NMR of -uridine has two multiplets at 5.72 ppm and 7.84 
ppm [20], respectively, which correspond to the 5 and 6 positions of the cytosine base 
pyrimidine moiety.  In-addition, the signals at 6.13, 4.27, 3.93, 3.77, and 3.88 ppm 
correspond to the 1, 3, 4, 5, and 5 protons, respectively.  The corresponding 13C 
NMR signals for positions 5, 6, 1, 3, 4, and 5 are at 102.98, 141.88, 85.29, 70.46, 
82.72, and 60.47 ppm, respectively. 
Another degradation product of gemcitabine is the α-isoform product II (Table 
11), which has structure similar to that of -uridine for the pyrimidine moiety and 
ribose base protons [30].  The 1H NMR spectrum of the isolated product has peaks at 
5.63 ppm and 7.53 ppm corresponding to the 5 and 6 positions of the cytosine base 
pyrimidine moiety.  The peaks with chemical shifts of 6.13, 4.05, 3.87, and 3.81 ppm 
are from 1, 3, 4, and 5 protons, respectively, which have similarities to the α-isomer 
product II [30] and -uridine [20] (Table 11).  For the cytosine base, the 13C NMR 
signals at positions 2, 4, 5, and 6 are 150.75, 164.46, 101.66, and 141.67 ppm, 
respectively; these signals are similar to those in α- or -uridine.  For the sugar moiety, 
the 13C signals at 114.92, 129.07, 70, 65.45 and 65.67 ppm are from carbons at 
positions 1, 2, 3, 4, and 5, respectively, which are similar to those from α-isomer 
product II [30] (Table 11). The DEPT-135 NMR data for isolated unknown products 
are provided in Table 11. 
The coupling constant (J) values for the protons located at the 1 position of the 
isoform product II [30] and isolated products are 19.61 Hz and 19.97 Hz, respectively 




proton and the adjacent fluorine atoms.  Similarly, the coupling constant values for 
the protons located at position 6 of the isoform product [30] and the isolated product 
are 2.62 Hz and 2.15 Hz, respectively (Table 11).  Based on the above data 
comparison, the isolated product was identified as 1-(2-deoxy-2,2-difluoro-α-D-
erythro-ribopyranosyl)pyrimidin-2,4(1H,3H)-dione (Scheme 4).   
Table 11: Comparative NMR assignments for -uridine, α-Isoform Impurity 
II and the Unknown Isolated Impurity 
 
Position -uridine [20] 
(Authentic 4*)  





























2 ---  151.93 --- 160 --- --- 150.75 151 
4 --- 165.62 --- 163 --- --- 164.46 168.9 
5 5.72 
(d, 1H) 
102.98 6.09 – 6.12 
(d, 1H) 






























2 --- 123.93 --- 118 --- --- 129.07 129 
3 4.27 
(m, 1H) 
70.46 4.12 – 4.16 
(m, 1H) 





82.72 3.94 – 4.00 
(m, 1H) 
 





60.47 3.85 – 3.92 
(m, 2H) 
65.8 65.8 3.78 - 3.81 
(m, 2H) 
65.67 65.67 
5 3.88 --- --- ---  --- --- --- 






D. CONCLUSIONS  
The degradation of gemcitabine injection solution follows pseudo first-order kinetic reactions.  
The pH-rate profile of gemcitabine shows three distinctive regions that are catalyzed by protons, 
solvent, and hydroxide ion; however, there might be something more than specific proton and 
hydroxyl catalysis are likely going on.  Gemcitabine molecule was more stable in the solvent 
region of pH range 7–9.5 than in lower and higher pH regions.  The stability of gemcitabine 
injection solution was determined at pH 2.5 and various temperatures for obtaining the Arrhenius 
plot. At pH 2.5, gemcitabine injection solution has a shelf-life of two years in refrigerated 
conditions and only two months at room temperature.  It is suggested that gemcitabine injection 
solution can be developed for refrigerated formulation. 
In neutral and alkaline solution, gemcitabine showed similar degradation products, but 
presumably through different mechanisms.  At neutral pH, the regularly observed degradation 
products were accompanied by another degradation product.  Thermal degradation of gemcitabine 
at 70°C for 4 weeks produced α- (0.01%) and -uridine (40%), in which water molecules act as 
acid and base.  In contrast. the degradation of gemcitabine in acidic media (1 N HCl) at 70°C 
for 4 weeks did not show any anomerization, which is consistent with the finding by Sally et al. 
[20] in the 40°C degradation study.  It is concluded that the formation of -uridine (40%) is due 
only to the thermal stress condition at 30°C, 40°C and 70°C. 
Anomerization products such as α-anomer (17%) of gemcitabine and α-uridine (8%) are 
formed under basic-stressed conditions (0.1 N NaOH) at 70°C.  Although -uridine (~ 20 %) is 
observed under this condition, it is at a lower level than in thermal- or acid-stressed conditions at 
70°C.  The higher level of α-uridine formation in basic-stressed solution at 70°C was due to 
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